Pharmeasy Share Price

Price Chart

PharmEasy, operated under API Holdings Limited, is one of India’s leading integrated digital healthcare platforms, offering end-to-end healthcare solutions across e-pharmacy, diagnostics, teleconsultation, and healthcare software. Founded in 2015 by Siddharth Shah, Hardik Dedhia, and Harsh Parekh, the company aims to improve access to affordable and reliable healthcare across India.

Through its consumer-facing PharmEasy app, the company enables on-demand home delivery of prescription medicines, over-the-counter healthcare products, nutraceuticals, and wellness essentials. PharmEasy has also built a strong diagnostics presence, providing home sample collection and diagnostic testing services across major Indian cities. These diversified healthcare verticals have made PharmEasy shares a closely tracked asset in the Indian unlisted market.

API Holdings’ ecosystem extends beyond consumer healthcare. Its subsidiaries include Retailio, a B2B pharmaceutical distribution platform serving pharmacies and hospitals, and Redbook, an enterprise resource planning (ERP) and pharmacy CRM solution that helps retail pharmacies manage inventory, billing, and operations. The group also offers teleconsultation and allied healthcare services, creating a vertically integrated healthcare delivery model that supports long-term scalability and revenue diversification.

In 2021, the company strengthened its diagnostics portfolio by acquiring a 66% stake in Thyrocare Technologies, becoming one of the first Indian unicorns to acquire a listed company. API Holdings has also launched PharmEasy SurgiCare, focusing on elective surgeries across key urban centers such as Mumbai, Delhi, Bengaluru, Chennai, Pune, and Indore.

API Holdings serves a wide network of pharmacies, hospitals, clinics, and healthcare providers across India, supported by a workforce of over 4,000 employees and an extensive partner pharmacy network. In recent developments, PharmEasy share price in the unlisted market has reflected ongoing capital restructuring efforts, including the company’s plan to raise approximately ₹2,400 crore through a rights issue, aimed at strengthening its balance sheet and meeting debt obligations.